Gemelli Biotech announced today that its diagnostic technologies will be featured across multiple research presentations at DDW 2026, the world's premier gathering of gastrointestinal researchers and ...
Biomerica, Inc. (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating the real-world clinical ...
Collaborators at the University of Michigan will present new Data on InFoods ® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ...
A study found that both the low FODMAP diet and rifaximin provide similar relief from IBS symptoms, and gut microbiome ...
inFoods IBS showed improvement in API similar to, and in some cases better than, current IBS drugs in the market NEWPORT BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), ...
Irritable bowel syndrome (IBS) is one of the most common conditions encountered by both primary care providers and gastroenterologists, with a pooled global prevalence of 11.2%. This functional bowel ...
A massive, nearly 20-year study tracking over 650,000 Americans with irritable bowel syndrome is raising new questions about the long-term safety of common treatments. Researchers found that some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results